References
- Lim S T, Hee S W, Quek R, Tao M. Performance status is the single most important prognostic factor in lymphoma patients aged greater than 75 overriding other prognostic factors such as histology. Leuk Lymphoma 2008; 49: 149–151
- A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project [see comments]. N Engl J Med 1993; 329: 987–994
- Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. The Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1997; 8: 973–978
- Maartense E, Hermans J, Kluin-Nelemans J C, Kluin P M, Van Deijk W A, Snijder S, et al. Elderly patients with non-Hodgkin's lymphoma: population-based results in The Netherlands. Ann Oncol 1998; 9: 1219–1227
- Rosenwald A, Wright G, Chan W C, Connors J M, Campo E, Fisher R I, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947
- Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne R D, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851–862
- Savage K J, Monti S, Kutok J L, Cattoretti G, Neuberg D, De Leval L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871–3879
- Fu K, Perry K D, Smith L M, Hans C P, Greiner T C, Chan W C, et al. Effect of addition of rituximab to CHOP on survival of patients in both the GCB and non-GCB subgroups of diffuse large B-cell lymphoma. J Clin Oncol 2007, Suppl: 451S, Abstract 840. 2007 ASCO Annual Meeting Proceedings
- Ganti A K, Weisenburger D D, Smith L M, Hans C P, Bociek R G, Bierman P J, et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol 2006; 17: 920–927
- Vose J M, Armitage J O, Weisenburger D D, Bierman P J, Sorensen S, Hutchins M, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1838–1844
- Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller A C, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634–641